National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Aurora A kinase/tyrosine kinase inhibitor ENMD-2076
An orally bioavailable synthetic small molecule with potential antiangiogenic and antineoplastic activities. Aurora A kinase/tyrosine kinase inhibitor ENMD-2076 selectively binds to and inhibits non-specified tyrosine kinases and Aurora kinases (AKs). The inhibition of AKs may result in the inhibition of cell division and proliferation and may induce apoptosis in tumor cells that overexpress AKs; antiangiogenic activity is related to the inhibition of angiogenic tyrosine kinases. AKs are serine-threonine kinases that play an essential role in mitotic checkpoint control during mitosis and are important regulators of cell division and proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:ENMD-2076



Previous:atvogen, Augmentin, Aurimmune, Aurolate, Aurora A kinase inhibitor MLN8237
Next:Aurora kinase inhibitor BI 811283, Aurora kinase inhibitor MLN8054, Aurora kinase inhibitor SNS-314, Aurora kinase/VEGFR2 inhibitor CYC116, autologous Ad-CD154-transduced CLL B cells

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov